DA Davidson Has Pessimistic Outlook of USNA FY2024 Earnings

USANA Health Sciences, Inc. (NYSE:USNA) – Analysts at DA Davidson dropped their FY2024 earnings per share estimates for USANA Health Sciences in a research note issued to investors on Wednesday, October 23rd. DA Davidson analyst L. Weiser now forecasts that the company will post earnings per share of $2.45 for the year, down from their prior estimate of $2.51. DA Davidson has a “Neutral” rating and a $35.00 price objective on the stock. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.50 per share. DA Davidson also issued estimates for USANA Health Sciences’ FY2025 earnings at $2.23 EPS.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, October 22nd. The company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.49 by $0.07. The firm had revenue of $200.22 million during the quarter, compared to analyst estimates of $208.45 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.80%. During the same period last year, the firm posted $0.59 EPS.

Separately, StockNews.com downgraded USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 24th.

USANA Health Sciences Trading Down 2.6 %

NYSE USNA opened at $36.81 on Thursday. USANA Health Sciences has a 12-month low of $34.15 and a 12-month high of $54.81. The company has a fifty day simple moving average of $37.90 and a two-hundred day simple moving average of $42.44. The stock has a market cap of $701.27 million, a P/E ratio of 11.47, a P/E/G ratio of 1.15 and a beta of 0.89.

Insider Buying and Selling

In other news, insider Paul A. Jones sold 6,266 shares of the company’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total value of $240,489.08. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, Director Gilbert A. Fuller sold 674 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $39.69, for a total transaction of $26,751.06. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Paul A. Jones sold 6,266 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total value of $240,489.08. The disclosure for this sale can be found here. Insiders sold 7,940 shares of company stock valued at $311,670 over the last quarter. 0.33% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On USANA Health Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. BOKF NA boosted its stake in shares of USANA Health Sciences by 274.5% during the 1st quarter. BOKF NA now owns 2,771 shares of the company’s stock worth $133,000 after acquiring an additional 2,031 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in USANA Health Sciences by 9.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company’s stock worth $284,000 after purchasing an additional 494 shares in the last quarter. DGS Capital Management LLC grew its holdings in USANA Health Sciences by 61.8% in the first quarter. DGS Capital Management LLC now owns 7,258 shares of the company’s stock valued at $352,000 after purchasing an additional 2,773 shares during the period. SG Americas Securities LLC purchased a new stake in shares of USANA Health Sciences in the second quarter valued at approximately $340,000. Finally, Exchange Traded Concepts LLC raised its stake in shares of USANA Health Sciences by 4.4% during the 3rd quarter. Exchange Traded Concepts LLC now owns 7,709 shares of the company’s stock worth $292,000 after buying an additional 322 shares during the period. Institutional investors and hedge funds own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.